1. Document reveals scope of Operation Warp Speed and underscores vast military involvement — New data bolsters Sarepta gene therapies for two deadly muscle diseases — Inovio forced to delay planned phase 2/3 testing of COVID vaccine — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

P&G ditches Pfizer, picks Merck’s consumer health business

Discussion in 'Pfizer' started by anonymous, Apr 19, 2018 at 10:04 AM.

  1. anonymous

    anonymous Guest

    After weeks of offers and speculations, a deal has finally been struck in the consumer health space, though not really in an expected manner. P&G has ditched Pfizer’s consumer health unit to buy the same business of rival Merck, which was eyed by Mylan NV.
    P&G was willing to pay $15 billion for Pfizer’s consumer health unit, but the latter demanded nothing short of $20 billion. However, instead of raising the bet, P&G found another seller in Merck and bought their consumer health business for about $4.21 billion.
    https://news.alphastreet.com/pg-ditches-pfizer-picks-mercks-consumer-health-business/